Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 292-298

  Feng, Qingping ^b   Lambert, Michelle L ^b   Callow, Ian D ^b   Arnold, J Malcolm O ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y RECEPTOR; NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; SYMPATHETIC NERVE; TONOMETRY; VENOCONSTRICTION;

EID: 0034073964     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104610     Document Type: Article

References (27)

1. 1. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659-60.
2. 2. Luberg JM, Terenius L, Hokfelt T, Goldstein M. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 1983; 42:167-72.
3. 3. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, et al. Neuropeptide Y distribution in the rat brain. Science 1983;221:877-9.
4. 4. Allen YS, Roberts GW, Bloom SR, Crow TJ, Polak JM. Neuropeptide Y in the stria terminalis: evidence for an amygdalofugal projection. Brain Res 1984;321:357-62.
5. 5. McDermott BJ, Millar BC, Piper HM. Cardiovascular effects of neuropeptide Y: receptor interactions and cellular mechanisms. Cardiovasc Res 1993;27:893-905.
6. 6. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
7. 7. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
8. 8. Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994;71:261-7.
9. 9. Lambert ML, Callow ID, Feng QP, Arnold JM. The effects of age on human venous responsiveness to neuropeptide Y. Br J Clin Pharmacol 1999;47:83-9.
10. 10. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981;11:237-43.
11. 11. Alradi A, Carruthers SG. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther 1985;38:495-502.
12. 12. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins: 1 & 2. Br J Clin Pharmacol 1994;38:181-96, 289-305.
13. 13. Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci 1987;40:47-54.
14. 14. Anton AH, Sayre DF. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 1962; 138:360-74.
15. 15. Hjemdahl P, Daleskog M, Kahan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci 1979;25:131-8.
16. 16. Edvinsson L, Ekman R, Thulin T. Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotensive in man. Regul Pept 1991;32:279-87.
17. 17. Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, et al. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 1982;116:477-80.
18. 18. Pernow J, Lundberg JM, Kaijser L, Hjemdahl P, Theodorsson Norheim E, Martinsson A, et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986;6:561-78.
19. 19. Pernow J, Schwieler J, Kahan T, Hjemdahl P, Oberle J, Wallin BG, et al. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am J Physiol 1989;257:H866-72.
20. 20. Pernow J, Lundberg JM, Kaijser L. Effect of oral administration of nifedipine on neuropeptide Y-and noradrenaline-induced vasoconstriction in the human. Clin Physiol 1989;9:67-75.
21. 21. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 1989;86:43-8.
22. 22. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59: 297-309.
23. 23. Forster C, Armstrong PW. Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. J Cardiovasc Pharmacol 1990;16:708-18.
24. 24. Teerlink JR, Gray GA, Clozel M, Clozel JP. Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium dependent: dissociation of basal and stimulated nitric oxide release. Circulation 1994;89:393-401.
25. 25. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
26. 26. Lind H, Erlinge D, Brunkwall J, Edvinsson L. Transient vasodilation induced by neuropeptide Y and inhibited by L-NMMA in human subcutaneous blood vessels [abstract]. Pharmacol Toxicol 1995;76(suppl IV):57.
27. 2-adrenoceptors and neuropeptide Y1 receptors in rats with heart failure. Acta Physiol Scand 1999;166:285-91.